Regulation system of expression using nuclear ppar receptors
CA 2375869 A1 · Owner: Darteil, Raphael · Inventors: Mahfoudi, Abderrahim; Staels, Bart; Darteil, Raphael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns novel methods and compositions for the pharmacological regulation of the expression of transgenes. More particularly it concerns a composition comprising: (a) a first element comprising a nucleic acid of interest under the control of an inducible promoter comprising an element containing a response element to a PPAR and a minimal transcriptional receptor; and (b) a second element comprising a nucleic acid coding for a PPAR under the control of a transcriptional promoter for simultaneous, separate or prolonged use. The invention concerns the use of said compositions and methods in the experimental clinical, therapeutic or diagnostic fields.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 22, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 22, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 22, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.